Cargando…
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
Background: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%–45% of gastric cancers, making them potential targets. Patients and methods: The prima...
Autores principales: | Iqbal, S., Goldman, B., Fenoglio-Preiser, C. M., Lenz, H. J., Zhang, W., Danenberg, K. D., Shibata, S. I., Blanke, C. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221514/ https://www.ncbi.nlm.nih.gov/pubmed/21415234 http://dx.doi.org/10.1093/annonc/mdr021 |
Ejemplares similares
-
Evaluation of Anti-inflammatory and Antimicrobial Activity of AHPL/AYCAP/0413 Capsule
por: Nipanikar, Sanjay, et al.
Publicado: (2017) -
Clinical and dosimetric experience with MammoSite‐based brachytherapy under the RTOG 0413 protocol
por: Wojcicka, Jadwiga B., et al.
Publicado: (2007) -
Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
por: Strickley, John D., et al.
Publicado: (2018) -
P04.13. Population-based case-control study of Chinese herbal products containing ephedra and cardiovascular disease risk
por: Lin, Y, et al.
Publicado: (2012) -
P.0413 Modifiable risk and protective factors influencing changes in subjective depression during the COVID-19-lockdown: identifying targets for prevention and intervention
por: Elek, L.P., et al.
Publicado: (2021)